End Of An Era As Generic Versions Of BMS’s Controversial Blockbuster Revlimid Arrive
Gradual Decline From $12bn Peak Expected
Executive Summary
Revlimid was the driving force behind Celgene’s growth, but also became symbolic in the ongoing row over US drug prices.